000			01730nam a2200253 4500
001			ESSALUD
005			20260805002026.0
007			ta
008			t pe ||||| |||| 00| 0 spa d
040			_aBMG
041			_aeng
100			_aDu Toit, George _eAutor _953889
245			_aPrevention and treatment of peanut allergy
300			_apáginas: 2449-2458
520			_aEarly introduction of peanut protein reduces allergy prevalence by approximately 80%, with efficacy diminishing as introduction is delayed. Appropriate prevention involves ingestion of approximately 2 g of peanut protein weekly for infants at low risk and 4 to 6 g weekly for infants at high risk. Population-level implementation that targets all infants achieves greater reduction in disease burden than approaches that target only high-risk groups, although disparities exist among some ethnic groups and groups with restricted access to care. Peanut immunotherapy initiated in younger children (1 to 3 years of age) shows superior efficacy and higher rates of clinical remission as compared with immunotherapy initiated in older children. The natural history of untreated peanut allergy follows a trajectory of increasing peanut-specific IgE levels and clinical reactivity over time, underscoring the importance of early intervention during this narrow developmental window.
650			_aALERGIA _97055
650			_aDERMATOLOGÍA _97479
650			_aMEDICINA CLINICA _933681
650			_aENFERMEDADES INFANTILES _953890
650			_aNUTRICIÓN
700			_aLack, Gideon _953891
773	0		_022717 _922639 _dMassachusetts NEJM Group _oNEJM006 _tThe New England Journal of Medicine _wESSALUD _x0028-4793
942			_cARTICULOS _e2026-07-31 _zSQB
999			_c22764 _d22764